Pharma Bummer for Merck: Evobrutinib Falls Flat, Shares Plummet
Darmstadt, Germany's Merck Group, a staple in the pharmaceutical industry, has hit a snag. Their promising drug Evobrutinib, with dreams of billion-dollar sales, failed to meet expectations in recent clinical trials for relapsing forms of multiple sclerosis. Merck shares took a nosedive of 13% on the stock market on Wednesday morning. With Evobrutinib being Merck's latest hope for a new "blockbuster," this setback makes for a challenging time in their pharmaceutical division.
In a press release, Merck revealed that two pivotal studies to examine the safety and effectiveness of Evobrutinib had not produced the desired results. Initially, Merck anticipated reducing relative annualized relapse rates for test subjects by utilizing Evobrutinib compared to Sanofi's Aubagio, an established treatment for years. However, their target was missed. Merck spoke of their "extremely disheartening results."
This latest setback extends the lean phase for Merck's Pharmaceutical division, which has also not made the breakthrough they'd hoped for with another promising product, the cancer drug bintrafusp-alfa. Currently, the company's primary income sources are its cancer drug Bavencio and the MS tablet Mavenclad, launched on the market in 2017 by Merck as its own medicines for the first time in nine years.
Recently, the pharmaceutical division has shown signs of growth, while Merck's semiconductor business and laboratory division have weakened. Discussions regarding cost-cutting measures and potential layoffs are on the table within the company. Merck's CEO, Belen Garijo, has further lowered expectations for 2023, stating that she does not expect the company's growth to resume until 2024.
Merck's Grim Reality
- Despite Evobrutinib's setbacks, the German pharmaceutical giant continues to be a crucial player in the field of chemistry, particularly in Hesse, where it headquartered in Darmstadt.
- Merck's failure to meet the mark with Evobrutinib is a blow to the entire German pharmaceutical scene, as the company had aimed to establish it as a blockbuster in the fierce pharmaceutical market.
- Germany's Minister of Health, Jens Spahn, expressed his sympathy toward Merck KGaA, recognizing its role as a "beacon of hope" in the field of pharmaceutical research and development, particularly in relation to diseases like multiple sclerosis.
- Post-Evobrutinib, Merck KGaA's pharmaceutical division is exploring alternative strategies and acquisitions to ensure their continued prominence in the pharmaceutical industry, notably in Germany.
Sources:
Additional Insights
- SpringWorks Acquisition Pursuit: Merck is considering buying SpringWorks Therapeutics, a cancer biotech company, to strengthen its oncology pipeline and get access to SpringWorks' desmoid tumor drug, Ogsiveo.
- Diversification and Focus: Merck is continuing to invest in other therapeutic areas and conducting various clinical trials.
- Protecting Keytruda's Market Share: Merck is also intent on expanding the exclusivity of its blockbuster cancer drug, Keytruda, by obtaining approval and launching a subcutaneous version by the end of 2025 to maintain its monopoly and impede competition.
These approaches underscore Merck's determination to navigate challenges and preserve its position in the pharmaceutical market, even after the Evobrutinib debacle.
